YIYasumori Izumi

Yasumori Izumi

*This is an algorithmically generated author record based on publicly available information.

Yasumori Izumi has a total of 46 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Protein induced by vitamin K absence or antagonist II (PIVKA‐II) producing large cell neuroendocrine carcinoma (LCNEC) of lung with multiple liver metastases: A case report

    by Hirokazu Kurohama, Yumi Mihara, Yasumori Izumi, Masatsugu Kamata, Seiji Nagashima, Atsumasa Komori, Yojiro Matsuoka, Nozomi Ueki, Masahiro Nakashima, Masahiro Ito

    A 78-year-old man was admitted to our hospital for multiple lung and liver tumors. Initial clinical diagnosis was hepatocellular carcinoma (HCC) with lung metastases because of a high value of serum protein induced by vitamin K absence or antagonist II (PIVKA-II) (6,705 mAU/mL). However, a review of a prior CT showed the lung tumor had existed 6 months before liver tumors were detected. The tumors progressed rapidly and the patient died 37 days after admission. Autopsy revealed that both lung and liver tumors exhibited the histology of large cell neuroendocrine carcinoma (LCNEC). Immunohistochemistry revealed that the tumor cells expressed not only neuroendocrine markers but also PIVKA-II diffusely. Hepatoid differentiation was not detected. Background liver did not show any chronic liver disease. The final diagnosis was PIVKA-II producing LCNEC of the lung with multiple liver metastases. PIVKA-II producing tumors other than HCC are extremely rare. To our best knowledge, this is the first case report of PIVKA-II producing neuroendocrine tumors of the lung.


  • Open Access

    Serum amyloid A triggers the mosodium urate -mediated mature interleukin-1β production from human synovial fibroblasts

    by Kiyoshi Migita, Tomohiro Koga, Kenshi Satomura, Masahiro Izumi, Takafumi Torigoshi, Yumi Maeda, Yasumori Izumi, Yuka Jiuchi, Taiichiro Miyashita, Satoshi Yamasaki, et al.

    Background: Monosodium urate (MSU) has been shown to promote inflammasome activation and interleukin-1β (IL-1β) secretion in monocyte/macrophages, but the cellular pathway and nod-like receptor family, pyrin domain containing 3 (NLRP3) inflammasome activation in synovial tissues, remain elusive. In this study, we investigated the effects of MSU on synovial fibroblasts to elucidate the process of MSU-mediated synovial inflammation. Methods: Human synovial fibroblasts were stimulated with MSU in the presence or absence of serum amyloid A (SAA). The cellular supernatants were analyzed by immunoblotting using anti-IL-1β or anti-caspase-1 antibodies. IL-1β or NLRP3 mRNA expressions were analyzed by real-time PCR or reverse transcription-PCR (RT-PCR) method. Results: Neither SAA nor MSU stimulation resulted in IL-1β or interleukin-1α (IL-1α) secretions and pro-IL-1β processing in synovial fibroblasts. However, in SAA-primed synovial fibroblasts, MSU stimulation resulted in the activation of caspase-1 and production of active IL-1β and IL-1α. The effect of SAA on IL-1β induction was impaired in cells by silencing NLRP3 using siRNA or treating with caspase-1 inhibitor. In addition, SAA induced the secretion of cathepsin B and NLRP3 mRNA expression in synovial fibroblasts. Conclusions: Our data demonstrate that exposure of human synovial fibroblasts to SAA promotes MSU-mediated caspase-1 activation and IL-1β secretion in the absence of microbial stimulation. These findings provide insight into the molecular processes underlying the synovial inflammatory condition of gout.


  • Open Access

    Inhibitory effects of the JAK inhibitor CP690,550 on human CD4+ T lymphocyte cytokine production

    by Kiyoshi Migita, Taiichiro Miyashita, Yasumori Izumi, Tomohiro Koga, Atsumasa Komori, Yumi Maeda, Yuka Jiuchi, Yoshihiro Aiba, Satoshi Yamasaki, Atsushi Kawakami, et al.

    The new JAK3 inhibitor, CP690,550, has shown efficacy in the treatment of rheumatoid arthritis. The present study was undertaken to assess the effects of CP690,550 on cytokine production and cellular signaling in human CD4+ T cells.


  • Open Access

    CP690,550 inhibits oncostatin M-induced JAK/STAT signaling pathway in rheumatoid synoviocytes

    by Kiyoshi Migita, Atsumasa Komori, Takafumi Torigoshi, Yumi Maeda, Yasumori Izumi, Yuka Jiuchi, Taiichiro Miyashita, Minoru Nakamura, Satoru Motokawa, Hiromi Ishibashi

    Introduction: Interleukin (IL)-6-type cytokines exert their effects through activation of the Janus kinase/signal transducers and activators of transcription (JAK/STAT) signaling cascade. The JAK/STAT pathways play an important role in rheumatoid arthritis, since JAK inhibitors have exhibited dramatic effects on rheumatoid arthritis (RA) in clinical trials. In this study, we investigated the molecular effects of a small molecule JAK inhibitor, CP690,550 on the JAK/STAT signaling pathways and examined the role of JAK kinases in rheumatoid synovitis. Methods: Fibroblast-like synoviocytes (FLS) were isolated from RA patients and stimulated with recombinant oncostatin M (OSM). The cellular supernatants were analyzed using cytokine protein chips. IL-6 mRNA and protein expression were analyzed by real-time PCR method and ELISA, respectively. Protein phosphorylation of rheumatoid synoviocytes was assessed by Western blot using phospho-specific antibodies. Results: OSM was found to be a potent inducer of IL-6 in FLS. OSM stimulation elicited rapid phosphorylation of STATs suggesting activation of the JAK/STAT pathway in FLS. CP690,550 pretreatment completely abrogated the OSM-induced production of IL-6, as well as OSM-induced JAK/STAT, and activation of mitogen-activated kinases (MAPKs) in FLS. Conclusions: These findings suggest that IL-6-type cytokines contribute to rheumatoid synovitis through activation of the JAK/STAT pathway in rheumatoid synoviocytes. Inhibition of these pro-inflammatory signaling pathways by CP690,550 could be important in the treatment of RA.


  • Open Access

    Successful Treatment of HTLV-1-Related Overlap Syndrome Using Tacrolimus

    by Yasumori Izumi, Hiroshi Kojima, Yasushi Koga, Kazuaki Yokota, Hideki Mori, Tadayoshi Ohno, Taiichiro Miyashita, Masahiro Ito, Masakatsu Motomura, Masanobu Mine, et al.

    A 56-year-old HTLV-I-positive woman, initially diagnosed as having Sjögren's syndrome, presented with muscle weakness, myalgia, face erythema and leg edema. Based on the presence of various autoantibodies, the diagnosis of overlap syndrome (dermatomyositis/Sjögren's syndrome) was made. Treatment with high-dose corticosteroid plus cyclosporine improved her symptoms. However, three months after the start of these treatments, exacerbation of myositis occurred. A muscle biopsy revealed prominent perivascular accumulation of mononuclear cells with perifascicular atrophy, which were consistent with dermatomyositis. Tacrolimus, which was substituted for cyclosporine led to marked improvement of the myositis symptoms.


    • 11 June 2010
      • Vol. 28, 111-2

    A case of gastric cancer presenting as polymyalgia rheumatica.

    by Yuki Yasunaga, Taichiro Miyashita, Junya Makiyama, Tomohiro Koga, Yasumori Izumi, Amane Kitazato, Shinichiro Kobayashi, Hikaru Fujioka, Ayako Matsumoto, Masahiro Ito, et al.